US Pharma MarketingTrodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow
Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV combo hits primary endpoint in two Phase 3 trials. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
Partners Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street.
The companies ...
Source: Endpoints News